Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Nephrology · Membranoproliferative Glomerulonephritis and C3 Glomerulopathy

Treatment Strategy: Standard of Care and New Targeted Therapies

At a Glance

Treatment for MPGN and C3G focuses on protecting kidney filters, reducing proteinuria, and calming the immune system. Options include essential supportive care, traditional immunosuppressants, and new FDA-approved targeted complement inhibitors like Iptacopan and Pegcetacoplan.

Treatment for MPGN (Membranoproliferative Glomerulonephritis) and C3G (C3 Glomerulopathy) has entered a new era. For many years, doctors relied on general treatments to slow kidney damage. Today, we have the first-ever medications designed specifically to target the root cause of these conditions. The goal of any treatment plan is threefold: protect the kidney filters, reduce proteinuria (protein in the urine), and calm the overactive immune system [1][2].

The Foundation: Supportive Care

Before starting intensive immune treatments, every patient needs a strong “supportive care” foundation. These medications protect the kidneys by reducing the physical stress on the filters [3][4]:

  • ACE Inhibitors or ARBs: These are blood pressure medications (like lisinopril or losartan) that lower the pressure inside the kidney’s filters, which significantly reduces the amount of protein leaking into your urine [3][5].
  • SGLT2 Inhibitors: Originally for diabetes, these drugs are now used in many kidney diseases to help protect kidney function and further reduce protein loss [6][7].
  • Statins and Diuretics: Statins help manage the high cholesterol often caused by kidney disease, while diuretics (“water pills”) help reduce the swelling (edema) in your legs and face [5][8].

Traditional Immunosuppression

If supportive care is not enough, your doctor may suggest “traditional” immune-system suppressors. These drugs turn down the body’s overall immune response. While they can be effective for some, their success varies from person to person [9][10]:

  • Corticosteroids (Prednisone): Used to quickly dampen inflammation, though they are often used only for short periods due to side effects [10].
  • MMF (Mycophenolate Mofetil): Often used as a “steroid-sparing” drug to maintain a calm immune system over the long term [11][12].
  • Rituximab: A drug that targets the cells that produce antibodies. It is more commonly used in IC-MPGN than in C3G [13].

A New Era: Targeted Complement Inhibitors

The most significant breakthrough in MPGN and C3G history is the recent FDA approval of targeted therapies. Rather than suppressing the whole immune system, these drugs act like a “surgical strike” on the specific complement pathway that is causing the damage [14][15].

  • Iptacopan (Fabhalta): An oral pill that inhibits Factor B. It blocks the “alternative pathway,” which is the central loop that stays stuck in the “on” position in patients with C3G [16][14].
  • Pegcetacoplan (Empaveli): A subcutaneous injection (under the skin) that inhibits C3, the very protein that deposits in the kidneys of C3G and primary IC-MPGN patients [14][17].

Both drugs have been shown to significantly reduce proteinuria and help stabilize kidney function in clinical trials [18][15].

The Future and Clinical Trials

Because MPGN and C3G are rare, clinical trials are the primary way patients can access the next generation of medicine. Researchers are currently testing drugs that target even more specific parts of the immune system, such as Factor D or MASP-2 [19][20]. If your current treatment is not working, asking your doctor about a clinical trial may provide a path toward a newer therapy [2][21].

Return to Home

Common questions in this guide

Why do I need blood pressure medications for MPGN or C3G?
Blood pressure medications like ACE inhibitors and ARBs are used to lower the pressure inside your kidney's filters. This protective effect significantly reduces the amount of protein leaking into your urine and helps prevent further kidney damage.
What are targeted complement inhibitors?
Targeted complement inhibitors act precisely on the specific immune pathways causing kidney damage, rather than suppressing your entire immune system. This targeted approach helps reduce proteinuria and stabilize kidney function more effectively for certain patients.
Am I a candidate for new complement inhibitors like Iptacopan or Pegcetacoplan?
These new therapies are recently FDA-approved for specific complement pathway issues in MPGN and C3G. Your nephrologist will evaluate your specific pathology report, kidney function, and proteinuria levels to determine if you are a good candidate.
What happens if my proteinuria doesn't improve with supportive care?
If supportive care isn't enough to reduce protein in your urine, your doctor may suggest traditional immunosuppression to calm your immune system. If standard treatments are ineffective, new targeted therapies or participating in a clinical trial may be the next step.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for the newly approved complement inhibitors like Iptacopan or Pegcetacoplan?
  2. 2.Is my blood pressure currently at the optimal level to protect my kidneys from further scarring?
  3. 3.Are there specific vaccinations I need to receive before starting a complement-inhibiting medication?
  4. 4.If my proteinuria doesn't improve with supportive care, what is the next step in my treatment plan?
  5. 5.Are there any clinical trials at this hospital or nearby that might be right for my specific diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Recurrence of C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis After Kidney Transplantation: Challenges and Opportunities.

    Ruiz-Cabello JE, Trujillo H, Cavero T, et al.

    Kidney international reports 2026; (11(2)):103682 doi:10.1016/j.ekir.2025.11.008.

    PMID: 41502804
  2. 2

    Delphi Consensus on Surrogate End Points in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

    Caravaca-Fontán F, Fakhouri F, Licht C, et al.

    Kidney international reports 2026; (11(2)):103671 doi:10.1016/j.ekir.2025.10.028.

    PMID: 41502799
  3. 3

    Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy.

    Bomback AS, Charu V, Fakhouri F

    Kidney international reports 2025; (10(1)):17-28 doi:10.1016/j.ekir.2024.09.017.

    PMID: 39810761
  4. 4

    Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative GN.

    Caravaca-Fontan F, Norouzi S, Huang M, et al.

    Kidney360 2026; (7(3)):547-559 doi:10.34067/KID.0000001059.

    PMID: 41359393
  5. 5

    Case Report of Spontaneous Remission of Biopsy-Proven Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

    Shah R, Segal MS, Wilkowski MJ

    Case reports in nephrology and dialysis 2017; (7(2)):81-90 doi:10.1159/000477660.

    PMID: 28868298
  6. 6

    Efficacy of iptacopan in idiopathic immune complex-mediated membranoproliferative glomerulonephritis refractory to conventional treatment.

    López Hidalgo R, Caba Molina M, Ruiz Escolano FJ, et al.

    Nefrologia 2026; (46(2)):501426 doi:10.1016/j.nefroe.2026.501426.

    PMID: 41688332
  7. 7

    Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.

    Bomback AS, Daina E, Remuzzi G, et al.

    Kidney international reports 2025; (10(1)):87-98 doi:10.1016/j.ekir.2024.09.030.

    PMID: 39810766
  8. 8

    Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.

    Nakagawa N, Mizuno M, Kato S, et al.

    PloS one 2021; (16(9)):e0257397 doi:10.1371/journal.pone.0257397.

    PMID: 34520493
  9. 9

    Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.

    Rudnicki M

    BioMed research international 2017; (2017()):2180508 doi:10.1155/2017/2180508.

    PMID: 28573137
  10. 10

    Rituximab treatment for immune-complex-mediated membranoproliferative glomerulonephritis.

    Lu Q, Zuo L, Dong B, et al.

    Immunotherapy 2018; (10(12)):1027-1031 doi:10.2217/imt-2018-0031.

    PMID: 30185139
  11. 11

    Idiopathic membranoproliferative glomerulonephritis treated with mycophenolate mofetil.

    Koratala A, Malpartida FR, Lee Loy J, Zeng X

    Clinical case reports 2018; (6(11)):2287-2288 doi:10.1002/ccr3.1826.

    PMID: 30455941
  12. 12

    [Benefit of therapeutic drug monitoring of immunosuppressants and immunomodulators in the management of autoimmune diseases].

    Djabarouti S, Mora P, Lahouati M, et al.

    La Revue de medecine interne 2022; (43(7)):412-418 doi:10.1016/j.revmed.2022.03.343.

    PMID: 35643786
  13. 13

    Hepatitis C-related membranoproliferative glomerulonephritis in the era of direct antiviral agents.

    Abdelhamid WAR, Shendi A, Zahran M, et al.

    Jornal brasileiro de nefrologia 2022; (44(2)):291-295 doi:10.1590/2175-8239-JBN-2020-0148.

    PMID: 33605311
  14. 14

    Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment.

    Filippone EJ, Farber JL

    Frontiers in nephrology 2026; (6()):1747678 doi:10.3389/fneph.2026.1747678.

    PMID: 41767602
  15. 15

    Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

    Fakhouri F, Bomback AS, Ariceta G, et al.

    The New England journal of medicine 2025; (393(22)):2210-2220 doi:10.1056/NEJMoa2501510.

    PMID: 41337715
  16. 16

    Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.

    Schubart A, Anderson K, Mainolfi N, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2019; (116(16)):7926-7931 doi:10.1073/pnas.1820892116.

    PMID: 30926668
  17. 17

    The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment

    Perry C, Von Buttlar X, Thota S

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2025; (42(2)):74-81 doi:10.4274/tjh.galenos.2025.2025.0054.

    PMID: 40257298
  18. 18

    Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

    Wong E, Nester C, Cavero T, et al.

    Kidney international reports 2023; (8(12)):2754-2764 doi:10.1016/j.ekir.2023.09.017.

    PMID: 38106570
  19. 19

    Structural characterization of Factor H via computational methods: Implications for disease and therapy.

    Jena AB, Duttaroy AK

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2025; (192()):118628 doi:10.1016/j.biopha.2025.118628.

    PMID: 41046580
  20. 20

    Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases.

    Escudero-Saiz VJ, Gonzalez Á, García-Herrera A, et al.

    Kidney medicine 2024; (6(6)):100823 doi:10.1016/j.xkme.2024.100823.

    PMID: 38741947
  21. 21

    Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis.

    Kavanagh D, Ariceta G, Vivarelli M, et al.

    Kidney international reports 2026; (11(1)):17-31 doi:10.1016/j.ekir.2025.10.020.

    PMID: 41541782

This page provides educational information about MPGN and C3G treatments. It does not replace professional medical advice. Always consult your nephrologist regarding the best treatment plan for your specific kidney condition.

Get notified when new evidence is published on Primary membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.